Table 4 Characteristics of oligometastatic secondary cancer (n = 9) receiving Tomotherapy
From: Hypofractionated radiotherapy for primary or secondary oligometastatic lung cancer using Tomotherapy
Case | Sex | Age | Stage | Pathological diagnosis | Dose (cGy x fx) | Intrathoracic Targets | Major systemic therapy | Status | Survival time (mo) |
|---|---|---|---|---|---|---|---|---|---|
1 | M | 68 | IVB | HCC | 500 × 8 + 450 × 3 | 1 | Thalidomide | A | 26.9 |
2 | M | 51 | IV | Sarcoma | 700 × 10 | 1 | Thalidomide | A | 60.5 |
3 | M | 71 | IVC | H&N SqCC | 500 × 10 | 1 | - | D | 6.3 |
4 | M | 61 | IV | Esophagus SqCC | 600 × 8 | 1 | - | D | 14.7 |
5 | M | 70 | - | Mesothelioma | 500 × 10 | 1 | - | A | 27.3 |
6 | M | 77 | IV | Colon AD | 550 × 10 | 2 | Xeloda | A | 43.7 |
7 | M | 82 | IV | Rectum AD | 450 × 13 | 1 | Xeloda | A | 53.7 |
8 | M | 63 | IV | Stomach AD | 450 × 12 | 2 | Xeloda | A | 37.2 |
9 | F | 77 | IV | Rectum AD | 450 × 9 | 4 | UFUR | D | 26.0 |